Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2020

01-05-2020 | Original Article – Clinical Oncology

Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung

Authors: Tomonari Oki, Keiju Aokage, Shogo Nomura, Kenta Tane, Tomohiro Miyoshi, Norihiko Shiiya, Kazuhito Funai, Masahiro Tsuboi, Genichiro Ishii

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2020

Login to get access

Abstract

Purpose

The purpose of this study was to determine the optimal method for measuring pathological invasive size that predicts prognosis in invasive mucinous adenocarcinoma (IMA).

Methods

We analyzed patients who underwent complete surgical resection for lung IMA. The invasive size of IMA was measured using two methods: (1) excluding lepidic method (ELM), that is, lepidic component was excluded from the invasive area regardless of alveolar mucin and (2) including lepidic method (ILM), that is, lepidic component was included as invasive area if alveolar space was filled with mucin. The prognostic predictability of ELM and ILM on survival was assessed using univariable and multivariable Cox regression models. The discriminative power was assessed using concordance probability estimate (CPE) and Akaike’s information criteria (AIC), and the prognostic impact of the newly redefined pathological stage according to ELM or ILM was also assessed.

Results

A total of 101 patients were included. The median invasive size via ELM and ILM was 1.4 cm (range, 0.0–7.7 cm) and 2.1 cm (range, 0.0–14.2 cm), respectively. ELM had better discriminative power than ILM (ELM, HR = 1.38, AIC = 110.19, CPE = 0.671; ILM, HR = 1.19, AIC = 111.52, CPE = 0.655). Although the survival curves based on ILM crossed between T3 and T4, the overall survival (OS) curves based on ELM were sufficiently distinct from one another.

Conclusions

ELM has higher discriminative power for OS, and thus the optimal method for measuring the pathological invasive size of IMA should exclude the lepidic component regardless of alveolar mucin.
Appendix
Available only for authorised users
Literature
Metadata
Title
Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung
Authors
Tomonari Oki
Keiju Aokage
Shogo Nomura
Kenta Tane
Tomohiro Miyoshi
Norihiko Shiiya
Kazuhito Funai
Masahiro Tsuboi
Genichiro Ishii
Publication date
01-05-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03158-1

Other articles of this Issue 5/2020

Journal of Cancer Research and Clinical Oncology 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.